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Hypercholesterolemia is a major risk factor for atherosclerotic
cardiovascular disease (ASCVD) [1]. Increased levels of low density
lipoprotein cholesterol (LDL-C) are associated with an increased* Corresponding author. Department of Pharmacological and Biomolecular Sci-
ences, University of Milan and IRCCS Multimedica, Via Balzaretti, 9, 20133, Milan,
Italy.
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1567-5688/© 2019 Elsevier B.V. This is an open access article under the CC BY-NC-ND Irisk of coronary heart disease (CHD) and many clinical trials have
shown that reducing LDL-C levels signiﬁcantly reduced the CHD
and CVD risk [2e5]. Thus LDL-C-lowering is the main approach for
the management of cardiovascular disease. Current guidelines
suggest LDL-C levels targets based on the individual CV risk; such
targets can be achieved by several means, which include both
lifestyle changes and pharmacological approaches [6], with statins
being the cornerstone of cardiovascular prevention. Several statins
are available and may be selected based on the individual patient
needs, therapeutic goals, tolerability and response to therapy.GO license (http://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
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cantly the CV risk in high and very-high CV, and especially ultra/
extremely high risk patients [7], and consequentially there may be
an indication to use a statin in combination with other non-statin
lipid-lowering drugs, such as ezetimibe, acting through a
different mechanism of action. The recently approved hypo-
cholesterolemic drugs, i.e. anti-PCSK9 monoclonal antibodies, have
offered the opportunity to further signiﬁcantly reduce LDL-C levels
and cardiovascular events in high CV risk patients already on statin
therapy [4,5]. However, they are still not commonly available due to
high costs of the therapy and lack of open reimbursement in most
of the European countries. Finally adding ezetimibe, with the
possibilities of additional 15e20% LDL-C reduction might be also
not enough in those with the highest cardiovascular risk [8]. That is
why there is a large unmet need to look for other agents with the
potent lipid-lowering properties [9].
A large part of the population is at low-to-moderate CV risk,
with LDL-C levels not far from those recommended. These subjects
are usually not eligible for lipid-lowering therapies and they are
generally advised with lifestyle changes, whichmay include dietary
changes and the addition of lipid-lowering dietary supplements or
nutraceuticals, such as phytosterols [6]. Among the latter groups,
also red yeast rice (RYR), obtained by the fermentation of common
rice with a fungus, has a hypocholesterolemic effect due to the
presence of bioactive constituents (monacolins) that inhibit
hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase (Fig. 1).
As suggested by current guidelines, nutraceuticals containing pu-
riﬁed RYR may be considered in subjects with CV risk not being on
the LDL-C goal, but not eligible for statin treatment, or unable to
tolerate statins [6]. It is also important to emphasize that nutra-
ceuticals, including RYR, cannot replace pharmaceutical therapy, as
only it is indicated.
Recently, the European Food Safety Authority (EFSA) has criti-
cally reviewed the scientiﬁc literature regarding the safety of di-
etary intake of monacolin K [10,11], raising uncertainties on such
topic. The objective of the present expert opinion paper is to discussFig. 1. Chemical structure of monacolin K and its mechanism of action. Monacolin K can be
pH value. When in its active form, monacolin K inhibits the endogenous synthesis of cho
reductase. Monacolin K is structurally identical to lovastatin.all the available clinical data on the use of RYR for human health,
and speciﬁcally for its cholesterol-lowering activity, to examine
both pros and cons, commenting on the potential biases of pub-
lished papers, and to provide a global and independent opinion on
the role of RYR in the control of lipid-associated cardiovascular risk
management.2. Introduction
2.1. General considerations on RYR and monacolin K
RYR is a nutraceutical produced by the fermentation of white
rice with the yeast Monascus purpureus mold and it has been used
for centuries in Asian food and medicine. It consists of several
bioactive components; among them, monacolins represent the
most attractive ones, as they are inhibitors of HMG-CoA reductase
(HMG-CoAR), the rate-limiting enzyme of the cholesterol biosyn-
thesis pathway (Fig. 1) [12e15]. Monacolin K is the most abundant
monacolin in RYR, being present both as a lactone and a hydroxy
acid forms, at a ratio depending mainly on the pH value; at low pH,
the lactone form predominates, whereas at neutral and basic pH
conditions the active hydroxy acid form is predominant; the con-
version of the lactone into its lipid-lowering active metabolite oc-
curs spontaneously at neutral and basic pH and independently of
the gut microbiota [16]. Cytochrome P450 (CYP450) enzymes and
P-glycoprotein are involved in the metabolism of monacolin K,
which suggests a potential interactionwith drugs that are primarily
metabolized through these pathways [17]. Furthermore, monacolin
K is structurally identical to lovastatin, and this identity raised
questions about the use of a “natural product” containing a mole-
cule, which is identical to a drug. RYR contains additional com-
pounds with potential lipid-lowering properties, including plant
sterols, isoﬂavones and monounsaturated fatty acids, and other
ingredients including fatty acids, pigments, and citrinin, a second-
ary toxic metabolite with the nephrotoxic properties produced
during fermentation [18].in the form of either lactone (inactive) or hydroxyl acid form (active), depending on the
lesterol by inhibiting the activity of hydroxymethylglutaryl-coenzyme A (HMG-CoA)
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olemic effect of RYR supplementation, in 2011 the European Food
Safety Authority (EFSA) approved a health claim regarding the
consumption of RYR as a food supplement containing monacolin K
(10mg) for themaintenance of normal blood LDL-cholesterol levels
[10]. However, due to the identity of monacolin K with lovastatin,
the EFSA recently raised safety concerns related to some side-
effects commonly associated with the treatment with statins [11].
3. The EFSA Scientiﬁc Opinion on RYR: facts and gaps
In 2011, a Scientiﬁc Opinion from EFSA Panel on Dietetic Prod-
ucts, Nutrition and Allergies established a causal relationship be-
tween the consumption of 10mg/day monacolin K from RYR and
the reduction of blood LDL-C levels [10].
Monacolin K in its lactone form is identical to lovastatin, a
hypocholesterolemic drug authorized in the European Union. Both
monacolin K and lovastatin are rapidly converted to the bioactive
hydroxyl acid form, which is responsible for the inhibitory activity
on HMG-CoAR. While this acidic active form is naturally present in
RYR (depending on pH), lovastatin is a prodrug and needs to be
converted from the lactone form [19].
It has been shown that the bioavailability of lovastatin may
signiﬁcantly increase when taken with a standard meal. In fact,
lovastatin is metabolized through the CYP3A4 isoform, and the
administration together with other drugs or food ingredients,
which inhibit this enzyme, may expose to higher plasma levels of
statins and increase the likelihood to experience drug-related
adverse events. Since CYP3A4 is also involved in the metabolism
of monacolin, despite of low doses applied, there is also a risk of
adverse effects due to interactions with other medicinal products
and/or foods.
Monacolin K, in the range 3e11.4mg, dose-dependently reduces
LDL-C levels, from 14.8% to 26.3% [20e25]. The proﬁle of adverse
events of monacolin K is comparable to that of lovastatin at similar
doses and therefore relatively safe and well-tolerated. Some case
reports have described adverse effects also with the lowest dose of
monacolin K, including cases of rhabdomyolysis, hepatitis and skin
disorders [26], however based on this data, causality between
therapy and observed symptoms cannot be conﬁrmed.
In August 2018 another Scientiﬁc Opinion on RYRwas presented
by the EFSA Scientiﬁc Panel [11]. The authors identiﬁed several
points of uncertainties, including a) the composition, the content
and the relative abundance of monacolins (which vary widely
among preparations) in food supplements containing RYR; b) the
variability of the ratio between monacolin K lactone and hydroxy
acid in RYR food supplements; c) the unknown bioactivity of
components in RYR other than monacolin K; d) the unfeasibility to
evaluate the safety of monacolins in certain groups of consumers
(pregnant women, nursing women, breastfed infants); e) the
possible interactions of RYR-based supplements with foods or
drugs inhibiting CYP3A4; f) the unknown interactions of mon-
acolins with other ingredient present in the supplement. This
might result in health risks following RYR consumption, whichmay
be speciﬁcally relevant to some vulnerable groups, including
pregnant women, people suffering from liver, kidney and muscle
disorders, persons aged over 70 years, and children and adolescents
[11].
During clinical trials, several adverse effects associated with the
intake of RYR-based products were reported, however they were
quantitatively similar to those observed during treatment with
lovastatin. In the period 2002eMay 2018, 82 cases of adverse ef-
fects to RYR were reported to the World Health Organization
(WHO) Vigibase; themost common ones weremusculoskeletal and
connective tissue disorders (39%), general disorders andadministration site conditions (32.9%), and gastrointestinal disor-
ders (18%) [11]. Between April 2002 and September 2015, the Italian
Surveillance System of Natural Health Products [26] collected 52
reports (3.7 cases/per year) concerning 55 adverse events over 14
years related to the consumption of RYR, three of which were
associated with a 3mg/day dose monacolin K [11]. Causality was
established for 34 (65%; 2.4 cases/per year) out of 52 clinical events.
The most frequent adverse events were musculoskeletal and con-
nective tissue disorders, gastrointestinal disorders, hepatobiliary
disorders and subcutaneous tissue disorders. In 14 cases (27%), the
reaction was fulﬁlling the criteria for seriousness, including 13
cases that required hospitalisation. The hepatic reactions reported
were classiﬁed as serious (acute hepatitis) in six out of ten cases.
However, sales data of all RYR-containing products were not
available, leading to the impossibility of calculating the actual
incidence of such adverse events. Adverse events (164 cases)
following RYR consumption have been also reported by the US Food
and Drug Administration (FDA) through a post-market surveillance
system in the period January 2004eSeptember 2017. The most
frequent adverse effects involved the musculoskeletal and con-
nective tissues (29.9%e38.4%). Cases of rhabdomyolysis were re-
ported with a relatively high rank of causality. Adverse effects on
the gastrointestinal system, skin and subcutaneous system, and the
hepatobiliary system were also relatively frequent [11]. The Panel
evidenced that the intake of RYR may be associated with other
botanicals or other drugs, which may account for possible side ef-
fect(s). However, the type of reported side effects (musculoskeletal
side effects with increase of creatine phosphokinase [CPK])
occurred after ingestion of monacolin K or lovastatin but not other
botanicals [11].
Based on these observation and the uncertainties highlighted in
this Scientiﬁc Opinion, the Panel concluded to be unable to identify
a dietary intake of monacolins from RYR not giving rise to concerns
about potentially harmful effects to health for the general popu-
lation, and as appropriate, for vulnerable subgroups of the popu-
lation [11].
It needs to be emphasized that the above mentioned numbers
must be compared with the real number of individuals on RYR
preparations therapy; thus the prevalence of RYR-related side ef-
fects, especially those deﬁned as serious, is much less than 0.1‰.
According to the report of one of the companies that produces RYR-
based nutraceuticals, which provided the EFSA signiﬁcant data of
exposure to consumers on food supplements containing 3mg of
monacolin K from RYR, a global incidence of adverse events was
estimated as 0.031% on the 1.613.053 exposed consumers; 0.0013%
of exposed consumers experienced a serious adverse event, and
only 0.0004% were conﬁrmed as serious and only related to the
speciﬁc food supplement. Moreover, it is worth noting that to date
only few cases of rhabdomyolysis have been reported (one of which
required hospitalization, while the other was deﬁned by CK in-
crease). In one case, rhabdomyolysis occurred at a daily intake of
3mg monacolin K in a subject with previous history of rhabdo-
myolysis related to simvastatin treatment [26]. The other case of
rhabdomyolysis occurred with a daily intake of 19.2mg monacolin
K [27]. A third case of rhabdomyolysis following the administration
of a dietary supplement containing monacolin K occurred in a 70-
year old woman under polytherapy including rosuvastatin and
sertraline; drug interaction seems to explain this case [28]. Some
individuals who experienced less severe muscle disorders
following the intake of monacolin K had a previous history of
muscle adverse events with statins [11]. It is well established that
several risk factors or pathological conditions may predispose to an
adverse reaction to statins (such as family history of muscle dis-
orders, history of CK elevation, vitamin D deﬁciency, coenzyme Q10
deﬁciency, extensive physical exercise, renal and hepatic
Table 1
Effect of XZK, an extract from RYR, on lipid proﬁle and coronary events in a popu-
lation with previous MI.
Plasma lipids % change (XZK vs placebo) p value
Total cholesterol 10.9% <0.001
LDL-C 17.6% <0.001
HDL-C þ4.2% <0.001
Non-HDL-C 16.6% <0.0001
TG 15.2% <0.001
Events risk reduction with XZK (95% CI) p value
Nonfatal MI 0.38 (0.27e0.54) <0.0001
Coronary disease mortality 0.69 (0.52e0.88) 0.005
Fatal MI 0.67 (0.38e1.20) 0.19
Fatal stroke 0.91 (0.42e1.99) 0.85
Coronary revascularization 0.64 (0.47e0.86) 0.004
CV mortality 0.70 (0.54e0.89) 0.005
Cancer mortality 0.44 (0.23e0.84) 0.014
Total mortality 0.67 (0.52e0.82) 0.0003
LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein
cholesterol; TG: triglycerides; MI: myocardial infarction; CV: cardiovascular.
Adapted from Lu Z. et al., Am J Cardiol, 2008; 101:1689e1693 [33].
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lowering therapy, untreated hypothyroidism, disorders of calcium
homeostasis, alcohol abuse, Asian ethnicity, low body mass index,
genetic polymorphisms), and this may also be true for RYR [29]. On
the other hand, not all the adverse events described were serious,
most of them were reversible, and some subjects had already
experiencedmuscle symptomswith previous statin treatment. This
suggests that patients who develop myopathy/myositis or rhab-
domyolysis (extremely rarely) have generally other co-morbidities,
which may predispose to such events (or drug-to-drug in-
teractions). Finally, many reported cases were without conﬁrmed
causality, and for all such cases we need to exclude all the risk
factors/conditions that might increase the risk of intolerance, so-
called drucebo effect, as well as use all the available tools,
including statin-associated muscle symptoms-clinical index
(SAMS-CI) with dechallenge and rechallenge to maximally increase
the chance for the reliable diagnosis of real RYR-related adverse
effects [30,31]. We also wish to stress that, despite the chemical
identity between monacolin K and lovastatin, the latter is admin-
istered as a single active ingredient, whereas monacolin K is only
one of the multiple components present in RYR preparations, and
also the ratio between the lactone and the hydroxyl acid formvaries
greatly among different preparations [32].
RYR is classiﬁed in Europe as a food supplement; it cannot hence
claim therapeutic effects e only drugs can e and no risk/beneﬁt
ratio can be considered. The EFSA Scientiﬁc Opinion did not take
into account some relevant information, which includes both
clinical data (see paragraph below) and data of exposure to con-
sumers on food supplements containing 3mg of monacolin K.
4. Data on the safety and efﬁcacy of RYR
The extract from red yeast Chinese rice known as Xuezhikang
(XZK) has been tested in a large multicenter, randomized, double
blind, placebo-controlled study conducted in 4870 Chinese patients
(18e70 y) with a previous documented myocardial infarction
(within 60 months prior to randomization) and increased levels of
creatine kinase (CK) to evaluate the effects on cardiovascular out-
comes [33]. The primary endpoint was the occurrence of a major
coronary event (nonfatal myocardial infarction [MI], or coronary
death, or cardiac death); secondary endpoints were total CV mor-
tality, total all-cause mortality, coronary revascularization, and
changes in lipid plasma levels. Patients enrolled received a twice-
daily treatment with XZK 600mg (300-mg capsule of XZK, corre-
sponding to 2.5e3.2mg monacolin K/capsule) or placebo, with an
average follow-up of 4.5 years. Mean LDL-C level at baseline was
129mg/dL. Patients who received XZK showed a signiﬁcant 17.6%
LDL-C level reduction compared with placebo (p< 0.001), and this
reduction was maintained throughout the study (Table 1). Overall,
the lipid proﬁle of patients treated with XZK was signiﬁcantly
improved (reduction of triglycerides and increase in HDL-C levels)
(Table 1) [33]. Patients treated with XZK had signiﬁcant decreases
in the incidence rates of cardiovascular outcomes, including
nonfatal MI (risk reduction [RR] 0.38, p< 0.0001), coronary mor-
tality (RR 0.69, p¼ 0.005), coronary revascularization (RR 0.64,
p¼ 0.004), CV mortality, (RR 0.70, p¼ 0.005) (Table 1). Moreover,
XZK signiﬁcantly reduced total mortality (RR 0.67, p¼ 0.0003) and
cancer mortality (RR 0.44, p¼ 0.014) (Table 1). This study did not
report treatment-related serious adverse events; discontinuation
rates and adverse events were similar between the two groups [33].
It is worth noting that this is the only clinical outcome trial on RYR
and that the high beneﬁcial effect of XZK might also depend on the
activities of non-statin components.
Since then, a large number of clinical studies has evaluated the
lipid-lowering efﬁcacy and safety of RYR and monacolin K. A meta-analysis of 20 RCTs with 6653 participants (follow-up between 2
months and 3.5 years) in which RYR with a known content of
monacolin K (dose varying from 4.8 to 24mg per day) was
compared with placebo or a statin showed that RYR supplemen-
tation reduced LDL-C levels compared with placebo (1.02mmol/
L/e39mg/dL); when compared to statin therapy (pravastatin
40mg, simvastatin 10mg, or lovastatin 20mg) there was no dif-
ference between the interventions [34]; the incidence of liver and
kidney adverse events was similar in all groups, as it was the
incidence of muscle symptoms [34]. The most recent, hitherto the
largest available meta-analysis on the safety of monacolin K
analyzed 53 randomized controlled trials including 8535 subjects
[35]. Monacolin K administration was not associated with an
increased risk of muscle adverse events (odds ratio [OR]¼ 0.94, 95%
conﬁdence interval [CI] 0.53, 1.65) or serious adverse events (OR
0.54, 95%CI 0.46, 0.64), and a signiﬁcant reduction in the risk of
non-muscle-related adverse events was observed (OR 0.59, 95%CI
0.50, 0.69) [35]. We should also acknowledge a recent case of acute
hepatitis 6 weeks after starting a RYR supplement and resolved
after stopping the supplement [36].5. Which patients/subjects might beneﬁt the most from RYR?
Statins are the most commonly prescribed drugs for the treat-
ment of hypercholesterolemia and CV risk reduction; a large
number of clinical trials have indicated a high efﬁcacy in reducing
LDL-C levels and the risk of cardiovascular events. However, in-
dividuals with moderate dyslipidemia and low CV risk are not
deemed for statin therapy by current guidelines and they are
usually advised with lifestyle intervention [6]. Furthermore, some
hypercholesterolemic patients may experience statin intolerance,
which signiﬁcantly reduces the adherence to therapy, limits an
effective treatment and increases their CV risk [37]. Furthermore,
for patients unwilling to take statins and/or other lipid-lowering
drugs even when clearly indicated and recommended by their
physicians, RYR might be a reasonable alternative compared to
other food supplements.
We must bear in mind that patients with conﬁrmed complete
statin intolerance should not be given RYR as it contains a statin.
However, a real statin intolerance affects only 3e5% of patients and
only very few (<1%) develop serious side-effects such as myopathy,
myositis or rhabdomyolysis (1.6 per 100,000 person-years) [29]. For
most (even 95%) of those who experienced statin-associated
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modifying the dose and type of statin, apply alternate-day statin
therapy, or alternatively a non-statin dug or speciﬁc nutraceuticals
with lipid-lowering properties can be considered [38]. RYR was
shown to reduce LDL-C levels by 20e30% in patients with SAMS
(even by 40% with ezetimibe), with a low discontinuation rate due
to recurrence of SAMS (2e7%) [39]. Since most patients have a
higher probability to report adverse events than healthy subjects of
the general population, a rigorous clinical assessment of statin
intolerance is mandatory and must take into account the possible
statin-use unrelated factors that may predispose to muscle symp-
toms [39].
Subjects in primary prevention with low-to-moderate hyper-
cholesterolemia (deﬁned as LDL-C levels mildly above the optimal
level, related to the individual CV risk), and thus still without clear
indications for statin therapy, as well as those with the indications
however with the high risk of new onset diabetes (NODM), may be
eligible for RYR use in order to reduce their LDL-C levels and CV risk.
Is RYR advisable also for subjects/patients who are not willing to
take a statin? We must underline that nutraceuticals, including
RYR, cannot replace statin/pharmacological therapy, but may be
used as add-on to non-statin lipid-lowering agents such as ezeti-
mibe to help achieving treatment targets; thus for such patients
who are unwilling to take statins they might be an important op-
tion of treatment [38].
6. Major critical points
Nutraceuticals do not require medical prescription and are
freely available (although we should acknowledge that low-dose
statins, i.e. simvastatin 10mg, can be also obtained without pre-
scription in some countries), whichmay give rise to some concerns.
Subjects who take RYR may be grouped into 2 categories:
 Individuals who freely buy and take RYR supplements con-
taining monacolin K: producers should label the product with a
clear indication stating that “before taking RYR it is recommended
to consult your doctor, especially if taking any other drug or food
supplement”. Cannot be mandatory, but patients should inform
their physician about the use of RYR for two main reasons: 1)
possible interaction with food or other drugs, 2) to report po-
tential adverse events (which may help the phytovigilance/
nutrivigilance). This aspect is of special relevance when taking a
product such as RYR, which can be endowed with a pharma-
cological effect.
 Subjects who come to the attention of the physician but are not
willing to take a statin. In any case, physicians must recommend
the use of a statin to lower LDL-C levels. Our recommendation is
that only subjects with low CV risk, without overt characteristics
of eligibility for statin therapy, or having conditions/risk factors
that may predispose to an increased risk of statin-associated
SAMS, may be advised to use RYR, and physicians should
discuss with the patients the possible beneﬁt as well as adverse
events associated with RYR use.
Another major critical point is the assurance of a high quality of
RYR containing products. To avoid the use of low quality products,
companies must declare the product content (list all substances
[and their doses] present in the nutraceutical), and guarantee the
absence of speciﬁc harmful component (list of what must not be
present at all or at least above certain levels). Citrinin is a neph-
rotoxic and hepatotoxic mycotoxin produced during the fermen-
tation of rice with Monascus, and may be present as a contaminant
in RYR preparations; an EU legal limit has been established at
2000 mg/kg, but a recent report found that this limit was exceededin some samples among those examined [40]. This ﬁnding suggests
the need of improved standardization of RYR products as well as
product labelling. This Expert Panel strongly recommends using
only citrinin-free RYR preparations.
In EU countries, between 2012 and 2018, 40 products have been
identiﬁed as clearly stating the content of monacolin K, with rec-
ommended daily intakes ranging from 2 to 48mg; however, for
most of them, the recommended maximal intake was 10mg, ac-
cording to the 2011 indication by EFSA. Only 8 out of 40 products
contained exclusively RYR preparation, whereas the others con-
tained several additional ingredients, which may contribute to the
hypocholesterolemic effect of RYR by acting via different mecha-
nisms of action. The combination of nutraceuticals allows achieving
LDL-C reductions by using lower doses of each component, and
thus reduces the likelihood of adverse events related to a single
component. Such products should be recommended due to their
higher efﬁcacy and safety (in comparison to those with single
component at higher doses) [38,41].6.1. Expert opinion
 From available data there is no clinical evidence of a higher
incidence of side effects with RYR up to 10mg/d than with
lovastatin at the same dose. With drugs we accept to have
adverse events, but nutraceuticals are not drugs; thus the
question rises what matters more, safety or beneﬁt? Beneﬁt is
important and needs to be balanced against safety; in the case of
RYR safety issues need to be coped with by sincere education/
detailed information on the packages.
 We must consider the overall beneﬁt of RYR for the general
population. Taking RYR would shift cholesterol levels to lower
and add CV beneﬁt, independently of starting cholesterol level
(Fig. 2). Mendelian randomization studies and clinical studies
indicate that this is clinically beneﬁcial [42].
 Absolute beneﬁt is related to the risk of the subjects. In the
general population in primary prevention the relative risk
reduction may be the same as high-risk population, but the
absolute risk reduction is obviously lower. The absolute number
of prevented events, however, may be quite relevant, because
most events occur in the large low and intermediate risk pop-
ulation; thus, a reduction of the mean level of LDL-C will shift
the whole distribution of exposure in a favourable direction
(Fig. 2). In this context, RYRmight represent a valuable tool with
a considerable impact at the population level. It is intuitive that
the adherence to RYR supplement intake is crucial to achieve the
LDL-C-lowering effect, and the prescribing physician should
make aware the subject that treatment will need to be followed
for years, and potentially life long.
 The clinical cardiovascular beneﬁt derives essentially from LDL-
C reduction, independently of how such a reduction is achieved.
However, we must emphasize that it is crucial to reduce LDL-C
safely, even when the approach is by means of nutraceuticals.
 Data on the exposure to RYR (used in a combination nutraceu-
tical, post-marketing surveillance data) have not been taken into
account in the EFSA Opinion. In our view, EFSA should consider
these data.
 Nutrivigilance should be applied on every commercial nutra-
ceutical; this will allow to monitor the effects of additional
components present in one RYR preparation but not in others
(and will avoid the “dilution” of the effect when an overall
nutrivigilance is performed on similar products). To implement
the post-marketing vigilance, we may suggest that producers
provide information on internet portals for side effect moni-
toring with the package inserts; this might be on a voluntary
Fig. 2. A large number of subjects at low risk may translate into a higher absolute number of events than the small number of patients at high risk. Reducing the mean LDL-C level of
the whole population would result in a global risk reduction (population approach); the risk reduction approach, aimed at moving high risk patients into normal range, is obtained
by appropriate interventions at the individual level.
Box 1
Recommendations to the Companies to improve the use of RYR
 Provide clear information on the quantity of monacolin K
 Inform clearly on restriction of use (especially pregnant
women) and risk
 Inform on interactions (other drugs or foods)
 Provide quality control data
Box 2
Missing scientific data
 Further specific trials in statin intolerant patients
 Studies to assess long-term compliance
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better deﬁned with formal regulations by the authorities.
 Available data suggest that the use of RYR is not associated with
a higher risk of adverse side effects than the use of statins. This
would raise the question on the possible indications of RYR in
subjects still without clear indications for statin therapy or those
with indications but having essentially higher risk of statin-
related side effects (NODM, obesity, carbohydrates distur-
bances, SAMS) [43].
 Should individuals be informed on what monacolin K is? This is
a point that requires consideration. This expert panel agrees that
the patient should be informed of the content of the product,
and the fact that it contains a “natural statin”. In our opinion the
right to be informed overcomes the fact that some subjects may
not be willing to take a product with this composition; espe-
cially for people who are not willing to take statin, as well as
those with the drucebo effect, the physician can address the
question of whether giving the patient the information that RYR
contains a natural statin might signiﬁcantly reduce the adher-
ence and compliance.
 Could the recent EFSA Scientiﬁc Opinion result in the ban of
selling RYR in the EU? What might be the consequences of this
banning?Mendelian randomization studies have suggested that
reducing LDL-C levels independent of the approach used results
in the reduction of CV risk and that lowering the plasma LDL-C
level earlier than is currently recommended, if maintained over
time, may result in proportionally greater reductions in the
lifetime CV risk than that suggested by short-term randomized
trials [1]. Patients with elevated LDL-C levels, who are not
eligible for statin therapy in view of their global CV risk, likely
beneﬁt from the use of RYR, due to its cholesterol-lowering
properties, allowing them to reduce their LDL-C levels and CV
risk [6]. As stated above, this may lead to preventing a large
number of cardiovascular events, which occur within the low-
to-intermediate risk population. Another group are those with
very high risk not willing to use statins/at the risk of statin
intolerance/non-adherent to statin therapy. For such patients
we need to reduce LDL-C, as they are at the highest risk of CVD
events [44]. The banning of RYR might result in an overall in-
crease of cardiovascular event incidence in a wide populationrange. It is also worth noting, on the other hand, that RYR-
containing products may be bought online or at black market,
which may result in an increased dissemination of low-quality
products and, as a consequence, a higher risk of adverse events.
 RYR may thus be considered to reduce the overall CV risk in the
general population; however, producer companies must be
asked to provide unequivocal, up to date, and clear information
on their products to prevent the use of low quality products.7. Conclusions
This Expert Panel believes that RYR-based food supplements
and nutraceuticals may play a role in reducing the global burden of
CV disease. An increased quality of food supplements and nutra-
ceuticals is an essential requirement to ensure safety of the product
and the protection of consumers. A post-marketing surveillance
must be mandatory for food supplements and nutraceuticals as it is
for drugs; this will also help to collect data on long-term safety.
Monacolin K at 3mg/day appears to essentially and safely reduce
LDL-C levels. (See Box 1, Box 2, Box 3)
Box 3
Recommendations to the doctor when prescribing RYR
 Clarify the indication of prescribing drugs or nutraceut-
icals containing statin in your patient. Does your patient
have sufficiently high cardiovascular risk?
 In case of reluctance of your patient to take classical sta-
tins, clarify the exact reason: (1) adverse effect (intolerant
patient), (2) specific worries about the chemical nature of
a drug (the patients prefer natural medicine) or (3) worries
about the statin administration in general.
 Based on this clarification, in cases 1 and 3, you should
inform your patients on the presence of a monacolin K
(¼ natural lovastatin) and its dose in the product.
 In any cases of prescription of product containing mon-
acolin K, be careful about contraindications, advise
regarding potential interactions and side effects (only if
the patient accepts to be informed on this), and monitor
lipid reduction and biological side effects (liver and
muscles).
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